Tentative FDA approval for 'TLE400' under PEPFAR

21 March 2017

The US Food and Drug Administration under the US President's Emergency Plan for AIDS Relief (PEPFAR) has approved the New Drug Application for efavirenz, lamivudine and tenofovir disoproxil fumarate tablets, 400mg/300mg/300mg ("TLE400").

TLE400, an antiretroviral (ARV) fixed-dose combination from Netherlands-incorporated Mylan (Nasdaq: MYL), will be available in developing countries as a first-line regimen for people being treated for HIV/AIDS. The company previously said it expects to make TLE400 availabe at $99 per patient per year..

Mylan's TLE400 is formulated with a 400mg dose of efavirenz, which is less than the standard dose of 600mg. The Kirby Institute's ENCORE1 trial, which used drugs provided by Mylan and Gilead Sciences (Nasdaq: GILD), showed that a reduced dose of 400mg efavirenz is non-inferior to a dose of 600mg, when combined with tenofovir and emtricitabine during 48 weeks in ART-naive adults with HIV-1 infection. TLE400 was recommended by the World Health Organization in 2016 as an alternative for first-line therapy for adults living with HIV.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK